Skip to main content

Antimicrobial Susceptibility Testing Market Size Worth USD 6.08 Billion in 2032 | Emergen Research

The growing resistance of microbes to different drugs is one of the significant factors influencing the antibiotic susceptibility testing/ antibiotic sensitivity testing market growth

Vancouver, Nov. 16, 2023 (GLOBE NEWSWIRE) — The global antimicrobial susceptibility testing market is projected to be worth USD 6.08 Billion by 2032, according to a current analysis by Emergen Research. The antimicrobial susceptibility testing/ antibiotic susceptibility testing market is observing high demand attributed to the growing resistance of microbes to drugs. Antimicrobial susceptibility testing/ antibiotic sensitivity testing is frequently done to ascertain the most appropriate bacterial infection treatment or determine the drug resistance of a specific bacterium strain. Antibiotic susceptibility testing, deployed to ascertain the candidate antibiotics’ effectiveness during the process of drug discovery and development, have led to increasing demand for rapid test kits for antibiotic susceptibility. For instance, bacteria release ATP (Adenosine triphosphate) during the growth in the presence of a suitable antibiotic. A susceptibility test comprises stimulating bacteria using an antibiotic and ascertaining if the bacteria can thrive in the antibiotic environment.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/381

Scope of Research

Report DetailsOutcome
Market size value in 2022USD 3.54 billion
CAGR (2023 – 2032)5.5%
Revenue forecast in 2032USD 6.08 billion
Base year for estimation2022
Historical data2019 – 2021
Forecast period2023 – 2032
Quantitative unitsRevenue in USD Millions, and CAGR from 2020 to 2032
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments coveredComponent, Type, Application, Method, End-Users, region
Regional scopeNorth America; Europe; Asia Pacific; Central & South America; MEA
Country scopeU.S.; Canada; Mexico; U.K.; Germany; France; Italy; Spain; China; India; Japan; South Korea; Brazil; Saudi Arabia; South Africa; Turkey
Key companies profiledDanaher Corporation, Merck KGaA, HiMedia Laboratories, Bruker Corporation, BioMerieux SA, Bio-Rad Laboratories, Precise Automation, Roche Diagnostics, Accelerate Diagnostics Inc., and Becton, Dickinson, and Company
Customization scope10 hrs of free customization and expert consultation

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @
https://www.emergenresearch.com/request-discount/381

MAJOR COMPANIES and Market Share Analysis

The leading players in the antimicrobial susceptibility testing/ antibiotic susceptibility testing/ antibiotic sensitivity testing market are equipped with enhanced production facilities and are involved in various R&D activities. A few leading players in the antimicrobial susceptibility testing/ antibiotic susceptibility testing/ antibiotic sensitivity testing market include:

  • Danaher Corporation
  • Merck KGaA
  • HiMedia Laboratories
  • Bruker Corporation
  • BioMerieux SA
  • Bio-Rad Laboratories
  • Precise Automation
  • Roche Diagnostics
  • Accelerate Diagnostics Inc.
  • Becton, Dickinson, and Company

In September 2020, Accelerate Diagnostics declared the receiving of the US Food and Drug Administration (FDA) approval for novel product improvements to the Accelerate Pheno® system to enhance effectiveness and increase the antimicrobial susceptibility testing menu system for blood infections.

Strategic Development

  • In February 2020, Becton, Dickinson, and Company made an announcement about the receiving of USD 6.0 million agreement with the Fleming Fund, a program by the Department of Healthcare and Social Care in the UK that aids low and middle-income nations worldwide to tackle antimicrobial resistance.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @
https://www.emergenresearch.com/select-license/381

Key Highlights From The Report

  • A molecule drug candidate cost to reach the market is presently projected at USD 2.50 billion, whereas the time to launch the drug to market is about ten years.
  • Antifungal susceptibility tests are crucial tools to conduct fungal disease treatment, understand the epidemiology of the local and worldwide disease, and recognize drug resistance to antifungals.
  • The antibiotic susceptibility testing/ antibiotic sensitivity testing market in the Asia-Pacific region is likely to grow at the fastest rate in the forecast period due to the growing incidence of infectious diseases, particularly in China and India, growing awareness in people about their healthy well-being, and rising deployment of over-the-counter antibiotics.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@
https://www.emergenresearch.com/industry-report/antimicrobial-susceptibility-testing-market

Emergen Research has segmented the global antimicrobial susceptibility testing/ antibiotic sensitivity testing/ antibiotic susceptibility testing market on the basis of Component, Type, Application, Method, End-Users, and region:

  • Component Outlook (Revenue, USD Billion; 2019-2032)
    • Manual Antimicrobial Susceptibility Testing Products
    • Automated Laboratory Instruments
    • Culture & Growth Media
    • Consumables
  • Type Outlook (Revenue, USD Billion; 2019-2032)
    • Antibacterial Susceptibility/Sensitivity Testing
    • Antiparasitic Susceptibility/Sensitivity Testing
    • Antifungal Susceptibility/Sensitivity Testing
    • Others
  • Application Outlook (Revenue, USD Billion; 2019-2032)
    • Drug Discovery & Development
    • Clinical Diagnostics
    • Epidemiology
    • Others
  • Method Outlook (Revenue, USD Billion; 2019-2032)
    • Disk Diffusion
    • Etest Method
    • Automated Susceptibility Testing  Instruments
    • Genotyping Method
    • Agar Dilution
  • End-Users Outlook (Revenue, USD Billion; 2019-2032)
    • Hospitals
    • Pharmaceutical Companies
    • Diagnostic Centers
    • Clinical Research Organizations
    • Research Institutes
  • Regional Outlook (Revenue, USD Billion; 2019-2032)
    • North America
      1. US.
      2. Canada
      3. Mexico
    • Europe
      1. Germany
      2. UK
      3. France
      4. BENELUX
      5. Rest of Europe
    • Asia Pacific
      1. China
      2. Japan
      3. South Korea
      4. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • MEA
      1. Saudi Arabia
      2. UAE
      3. Rest of MEA

Curated Reports You Shouldn’t Miss: Dive In Now!

Powered Surgical Instruments Market, By Product (Electric Instruments, Battery-Powered Instruments, and Others), By Application, and By Region Forecast to 2032

Cannula Market, By Product (Cardiac, Dermatology, Nasal, Arthroscopy, and Others), By Type (Neonatal, Straight, Winged, and Others), By Material, By Size, By Application, By End-Use, and By Region Forecast to 2032

Bacteriophage Market, By Product Type (Phage Probiotics and Phage Therapeutics), By Route of Administration (Oral, Topical, and Others), By Application, By Distribution Channel, and By Region Forecast to 2032

Spatial Omics Technologies Market, By Product Type (Instruments, Consumables, and Software), By Technology, By End-use, By Region Forecast to 2032

Surgical Stapling Devices Market, By Product Type (Powered Surgical Stapling Device and Manual Surgical Stapling Device), By Type (Re-usable and Disposable), By Application, By End-Use, and By Region Forecast to 2032

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Japanese Version: Antimicrobial Susceptibility Testing Market

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Read our Press Release @ https://www.emergenresearch.com/press-release/global-antimicrobial-susceptibility-testing-market

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.